Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

CXCR3 Identifies Human Naive CD8+ T Cells with Enhanced Effector Differentiation Potential.

De Simone G, Mazza EMC, Cassotta A, Davydov AN, Kuka M, Zanon V, De Paoli F, Scamardella E, Metsger M, Roberto A, Pilipow K, Colombo FS, Tenedini E, Tagliafico E, Gattinoni L, Mavilio D, Peano C, Price DA, Singh SP, Farber JM, Serra V, Cucca F, Ferrari F, Orrù V, Fiorillo E, Iannacone M, Chudakov DM, Sallusto F, Lugli E.

J Immunol. 2019 Dec 15;203(12):3179-3189. doi: 10.4049/jimmunol.1901072. Epub 2019 Nov 18.

2.

Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming.

Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, Andreata F, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti LG, Iannacone M.

Nature. 2019 Oct;574(7777):200-205. doi: 10.1038/s41586-019-1620-6. Epub 2019 Oct 2.

PMID:
31582858
3.

The role of type I interferons in CD4+ T cell differentiation.

Kuka M, De Giovanni M, Iannacone M.

Immunol Lett. 2019 Nov;215:19-23. doi: 10.1016/j.imlet.2019.01.013. Epub 2019 Feb 13. Review.

PMID:
30771379
4.

The conduit system exports locally secreted IgM from lymph nodes.

Thierry GR, Kuka M, De Giovanni M, Mondor I, Brouilly N, Iannacone M, Bajénoff M.

J Exp Med. 2018 Dec 3;215(12):2972-2983. doi: 10.1084/jem.20180344. Epub 2018 Nov 14.

5.

Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection.

Jofra T, Di Fonte R, Galvani G, Kuka M, Iannacone M, Battaglia M, Fousteri G.

Eur J Immunol. 2018 Aug;48(8):1389-1399. doi: 10.1002/eji.201747316. Epub 2018 May 30.

6.

Intravital Imaging of B Cell Responses in Lymph Nodes.

Sammicheli S, Kuka M, Iannacone M.

Methods Mol Biol. 2018;1763:63-74. doi: 10.1007/978-1-4939-7762-8_7.

PMID:
29476489
7.

Viral subversion of B cell responses within secondary lymphoid organs.

Kuka M, Iannacone M.

Nat Rev Immunol. 2018 Apr;18(4):255-265. doi: 10.1038/nri.2017.133. Epub 2017 Dec 18. Review.

PMID:
29249807
8.

Intestinal Flossing Keeps Pathogens at Bay.

Kuka M, Iannacone M.

Dev Cell. 2017 Nov 20;43(4):383-384. doi: 10.1016/j.devcel.2017.11.006. Review.

9.

Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.

Jofra T, Galvani G, Kuka M, Di Fonte R, Mfarrej BG, Iannacone M, Salek-Ardakani S, Battaglia M, Fousteri G.

Front Immunol. 2017 Jul 12;8:811. doi: 10.3389/fimmu.2017.00811. eCollection 2017.

10.

Inflammatory monocytes hinder antiviral B cell responses.

Sammicheli S, Kuka M, Di Lucia P, de Oya NJ, De Giovanni M, Fioravanti J, Cristofani C, Maganuco CG, Fallet B, Ganzer L, Sironi L, Mainetti M, Ostuni R, Larimore K, Greenberg PD, de la Torre JC, Guidotti LG, Iannacone M.

Sci Immunol. 2016 Oct 21;1(4). pii: eaah6789.

11.

PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.

Fousteri G, Jofra T, Di Fonte R, Kuka M, Iannacone M, Battaglia M.

Clin Immunol. 2015 Feb;156(2):98-108. doi: 10.1016/j.clim.2014.12.002. Epub 2014 Dec 13.

PMID:
25513733
12.

The role of lymph node sinus macrophages in host defense.

Kuka M, Iannacone M.

Ann N Y Acad Sci. 2014 Jun;1319:38-46. doi: 10.1111/nyas.12387. Epub 2014 Mar 4. Review.

PMID:
24592818
13.

A method for high purity sorting of rare cell subsets applied to TDC.

Kuka M, Ashwell JD.

J Immunol Methods. 2013 Dec 31;400-401:111-6. doi: 10.1016/j.jim.2013.10.002. Epub 2013 Oct 11.

14.

CD70 is downregulated by interaction with CD27.

Kuka M, Munitic I, Giardino Torchia ML, Ashwell JD.

J Immunol. 2013 Sep 1;191(5):2282-9. doi: 10.4049/jimmunol.1300868. Epub 2013 Aug 2.

15.

CD70 deficiency impairs effector CD8 T cell generation and viral clearance but is dispensable for the recall response to lymphocytic choriomeningitis virus.

Munitic I, Kuka M, Allam A, Scoville JP, Ashwell JD.

J Immunol. 2013 Feb 1;190(3):1169-79. doi: 10.4049/jimmunol.1202353. Epub 2012 Dec 26.

16.

Identification and characterization of polyclonal αβ-T cells with dendritic cell properties.

Kuka M, Munitic I, Ashwell JD.

Nat Commun. 2012;3:1223. doi: 10.1038/ncomms2223.

17.

DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells.

Cavalieri D, Rivero D, Beltrame L, Buschow SI, Calura E, Rizzetto L, Gessani S, Gauzzi MC, Reith W, Baur A, Bonaiuti R, Brandizi M, De Filippo C, D'Oro U, Draghici S, Dunand-Sauthier I, Gatti E, Granucci F, Gündel M, Kramer M, Kuka M, Lanyi A, Melief CJ, van Montfoort N, Ostuni R, Pierre P, Popovici R, Rajnavolgyi E, Schierer S, Schuler G, Soumelis V, Splendiani A, Stefanini I, Torcia MG, Zanoni I, Zollinger R, Figdor CG, Austyn JM.

Immunome Res. 2010 Nov 19;6:10. doi: 10.1186/1745-7580-6-10.

18.

Src kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists.

Kuka M, Baronio R, Valentini S, Monaci E, Muzzi A, Aprea S, De Gregorio E, D'Oro U.

PLoS One. 2010 Jul 9;5(7):e11491. doi: 10.1371/journal.pone.0011491.

19.

Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism.

Rizzetto L, Kuka M, De Filippo C, Cambi A, Netea MG, Beltrame L, Napolitani G, Torcia MG, D'Oro U, Cavalieri D.

J Immunol. 2010 Apr 15;184(8):4258-68. doi: 10.4049/jimmunol.0902972. Epub 2010 Mar 12.

20.

Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.

Casnici C, Volpe G, Lattuada D, Crotta K, Kuka M, Panuzzo C, Mastrotto C, Tonon G, Fazio VM, Saglio G, Marelli O.

Cancer Lett. 2009 Apr 8;276(1):61-7. doi: 10.1016/j.canlet.2008.10.032. Epub 2008 Dec 4.

PMID:
19062160
21.

Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.

Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G.

Cancer Res. 2007 Jun 1;67(11):5300-7.

Supplemental Content

Support Center